Status:

UNKNOWN

Influence of Caffeine Therapy in Preterm Infants

Lead Sponsor:

Marmara University

Conditions:

Caffeine; Sleep Disorder

Eligibility:

All Genders

28-34 years

Brief Summary

The development of sleep wake cycles is indicative of child's neurocognitive functions. Caffeine therapy is commonly used in neonatal intensive care units for treatment of apnea of prematurity (AOP), ...

Detailed Description

Methylxanthines have been prescribed in preterm infants to treat and prevent Apnea of Prematurity (AOP), for extubation success, for reduction of incidence of BPD, need for treatment of PDA, retinopat...

Eligibility Criteria

Inclusion

  • Preterm infants born between 28 to 34 gestational weeks admitted to the Marmara University Neonatal Intensive Care Unit (NICU)

Exclusion

  • perinatal asphyxia intraventricular hemorrhage grade 3 or higher retinopathy of prematurity(ROP) of stage 3 or higher major congenital anomalies infants using sedative or anticonvulsant drugs at the time of data collection

Key Trial Info

Start Date :

May 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

May 1 2021

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT04376749

Start Date

May 1 2020

End Date

May 1 2021

Last Update

May 6 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Marmara University School of Medicine

Istanbul, Turkey (Türkiye)